Drugs / Mocetinostat
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04299113 | May 2020 → Dec 2026 expected | rhabdomyosarcoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03565406 | Apr 2018 → Jan 2020 | melanoma | NYU Langone Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02993991 | Oct → Dec 2017 | oral cavity squamous cell carcinoma | University Health Network, Toronto | Withdrawn | No outcome recorded |
| Phase 1 | NCT03220477 | Aug 2017 → Jul 2026 overdue | lung cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00324194 | Feb 2005 → Mar 2008 | leukemia, myelodysplastic syndrome | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00324129 | Feb 2005 → Jul 2006 | leukemia, myelodysplastic syndrome | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00323934 | Apr 2004 → Oct 2007 | non-Hodgkin lymphoma | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT02805660 | Jun 2016 → Dec 2019 | cancer of unknown primary site | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02429375 | Apr 2015 → Feb 2021 | Hodgkins lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02282358 | Oct 2014 → May 2023 | B-cell non-Hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02018926 | Dec 2013 → Sep 2015 | myelodysplastic syndrome | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00372437 | Sep 2006 → Dec 2008 | neoplasm | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00324220 | Jan 2006 → Nov 2008 | acute myeloid leukemia, myelodysplastic syndrome | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 29 trials · 1 missed | ||||||
| Phase 2 | NCT02954991 | Nov 2016 → Nov 2021 | non-small cell lung carcinoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02303262 | Nov 2015 → Dec 2016 | leiomyosarcoma | Sarcoma Alliance for Research through Collaboration | Completed | No outcome recorded |
| Phase 2 | NCT02236195 | Oct 2014 → Apr 2016 | urothelial carcinoma | Mirati Therapeutics Inc. | Completed | Missed primary |
| Phase 2 | NCT00666497 | Jun 2008 → Apr 2009 | acute myeloid leukemia, myelodysplastic syndrome | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00543582 | Oct 2007 → Mar 2009 | B-cell non-Hodgkin lymphoma, Hodgkins lymphoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00431873 | Jan 2007 → Nov 2008 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00374296 | Sep 2006 → Sep 2008 | acute myeloid leukemia, myelodysplastic syndrome | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00359086 | Aug 2006 → Jan 2012 | lymphoma | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00358982 | Aug 2006 → Jan 2009 | Hodgkins lymphoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00511576 Comparator | Aug 2007 → Mar 2009 | breast cancer, gastric cancer, non-small cell lung carcinoma, prostate cancer | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mocetinostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02282358 ↗ |
| Known as | 2HBr | “The first part of the study is to evaluate and determine if three different forms of MGCD0103 (free base FB-MGCD0103, tartaric acid free base \[TA-FB-MGCD0103\], and...” NCT00543582 ↗ |
| Known as | FB-MGCD0103 | “The first part of the study is to evaluate and determine if three different forms of MGCD0103 (free base FB-MGCD0103, tartaric acid free base \[TA-FB-MGCD0103\], and...” NCT00543582 ↗ |
| Known as | MG-0103 | “The purpose of the first part (Phase 1) of this study is to find out what side effects the experimental drug MG-0103 in combination with azacitidine has on your body.” NCT00324220 ↗ |
| Known as | MGCD0103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00431873 ↗ |
| Known as | TA-FB-MGCD0103 | “The first part of the study is to evaluate and determine if three different forms of MGCD0103 (free base FB-MGCD0103, tartaric acid free base \[TA-FB-MGCD0103\], and...” NCT00543582 ↗ |
| Action | Inhibit | “Histone deacetylase 11 inhibitor” CHEMBL272980 ↗5“Histone deacetylase 2 inhibitor” CHEMBL272980 ↗ “Histone deacetylase 8 inhibitor” CHEMBL272980 ↗ “Histone deacetylase 3 inhibitor” CHEMBL272980 ↗ “Histone deacetylase 1 inhibitor” CHEMBL272980 ↗ “histone deacetylase inhibitor” NCT00358982 ↗ |
| Modality | Small molecule | “Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor” NCT02993991 ↗ |
| Route | Oral | “Oral dosage 2 times weekly.” NCT00323934 ↗ |
| Target | HDAC1 | “Histone deacetylase 1 inhibitor” CHEMBL272980 ↗ |
| Target | HDAC11 | “Histone deacetylase 11 inhibitor” CHEMBL272980 ↗ |
| Target | HDAC2 | “Histone deacetylase 2 inhibitor” CHEMBL272980 ↗ |
| Target | HDAC3 | “Histone deacetylase 3 inhibitor” CHEMBL272980 ↗ |
| Target | HDAC8 | “Histone deacetylase 8 inhibitor” CHEMBL272980 ↗ |